ALK's tablet trial in Ukraine set to continue
Despite the conflict between Russia and Ukraine, the allergy firm has ongoing pediatric trials in both countries. CEO Carsten Hellmann was initially surprised that this was possible in a warzone.
by ulrich quistgaard, translated by daniel pedersen
ALK is currently testing its tablet against house dust mite allergies in children in a large phase III study taking place across the US and Europe. The company finished enrollment earlier this year – and among the patient population are people from Ukraine and Russia.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK releases surprisingly strong quarterly figures
For subscribers
